Marken and Acres Announce Partnerships Streaming Clinical Trial Logistics

Marken, the leading clinical logistics organization, and the Alliance for Clinical Research Excellence and Safety (ACRES), a multi-sector non-profit dedicated to excellence in clinical research, have created a strategic partnership with the goal of enhancing the precision, speed and transparency of the storage and transport of clinical trial materials around the world.

Marken is 100% dedicated to life science and has been providing supply chain logistics solutions for 35 years. With 10 Marken-owned depots and more than 41 locations around the world, it collects, stores and delivers materials globally. Marken offers round trip solution services, including API distribution, pre-clinical services, kit building, packaging, drug return and destruction, GPS tracking, direct to patient delivery, regulatory consulting, and cutting edge information technology systems that enable real time monitoring, management and data collection 24/7 from any location in the world.

Using an Integrated Logistics Model (ILM) as a centralized approach to consolidate ancillary items allows Marken to serve its clients as one global partner offering end-to-end solutions with one global depot and warehouse network; one global inventory management system; greater buying power through centralized procurement; and consolidated shipments.

ACRES is working to bring together organizations, companies and individuals from all facets of the clinical research sector to work together to build a shared global system for safe, high-performance, clinical research. “Marken’s service model nicely aligns with the initiatives ACRES has already begun and will be a great support in developing a comprehensive clinical research system,” said Greg Koski, ACRES Co-founder and CEO.

Wes Wheeler, Marken’s Chief Executive Officer says, “We look forward to using our experience and expertise to guide the clinical supply logistics component of ACRES endeavor to create a collaborative global system for clinical research.”

  • <<
  • >>

Join the Discussion